Details

Autor(en) / Beteiligte

• Baeten, Jared M
• Palanee-Phillips, Thesla
• Brown, Elizabeth R
• Schwartz, Katie
• Soto-Torres, Lydia E
• Govender, Vaneshree
• Mgodi, Nyaradzo M
• Matovu Kiweewa, Flavia
• Nair, Gonasagrie
• Mhlanga, Felix
• Siva, Samantha
• Bekker, Linda-Gail
• Jeenarain, Nitesha
• Gaffoor, Zakir
• Martinson, Francis
• Makanani, Bonus
• Pather, Arendevi
• Naidoo, Logashvari
• Husnik, Marla
• Richardson, Barbra A
• Parikh, Urvi M
• Mellors, John W
• Marzinke, Mark A
• Hendrix, Craig W
• van der Straten, Ariane
• Ramjee, Gita
• Chirenje, Zvavahera M
• Nakabiito, Clemensia
• Taha, Taha E
• Jones, Judith
• Mayo, Ashley
• Scheckter, Rachel
• Berthiaume, Jennifer
• Livant, Edward
• Jacobson, Cindy
• Ndase, Patrick
• White, Rhonda
• Patterson, Karen
• Germuga, Donna
• Galaska, Beth
• Bunge, Katherine
• Singh, Devika
• Szydlo, Daniel W
• Montgomery, Elizabeth T
• Mensch, Barbara S
• Torjesen, Kristine
• Grossman, Cynthia I
• Chakhtoura, Nahida
• Nel, Annalene
• Rosenberg, Zeda
• McGowan, Ian
• Hillier, Sharon

Titel

Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women

Ist Teil von

• The New England journal of medicine, 2016-12, Vol.375 (22), p.2121-2132

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

Elektronische Zeitschriftenbibliothek (Open access)

Beschreibungen/Notizen

• Development of HIV-1 prevention methods is a global priority. In this randomized, controlled trial in sub-Saharan Africa, a vaginal ring containing the antiretroviral dapivirine was 27% effective in protecting against HIV-1 acquisition. More than half of the 35 million persons currently living with human immunodeficiency virus type 1 (HIV-1) infection are women. A majority of these women reside in sub-Saharan Africa, 1 a region that has some of the highest incidences of HIV-1 infection in any population worldwide. 2 – 4 The use of antiretroviral medications as pre-exposure prophylaxis is a promising approach to the prevention of HIV-1 acquisition. 5 Several clinical trials of the antiretroviral tenofovir showed such protection against HIV-1. 2 , 6 – 8 However, in three trials involving African women, adherence to tenofovir-containing pills and vaginal gels was low, and HIV-1 protection was not shown. . . .